Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Gynecologic 1

Conditions

Ovarian Neoplasms 34Uterine Cervical Neoplasms 24Fallopian Tube Neoplasms 18Endometrial Neoplasms 16Neoplasm Metastasis 10Lung Neoplasms 9Pancreatic Neoplasms 8Stomach Neoplasms 7Colorectal Neoplasms 7Carcinoma, Transitional Cell 7Breast Neoplasms 7Melanoma 6Carcinoma, Renal Cell 6Prostatic Neoplasms 5Esophageal Neoplasms 5Carcinosarcoma 5Carcinoma, Hepatocellular 5Vaginal Neoplasms 4Triple Negative Breast Neoplasms 4Thyroid Neoplasms 4Colonic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Urinary Bladder Neoplasms 3Testicular Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma 3Multiple Myeloma 3Cholangiocarcinoma 3Brain Neoplasms 3Vulvar Neoplasms 2

Interventions

rocakinogene sifuplasmid 1pembrolizumab 1durvalumab 1atezolizumab 1Vaccines 1VGX-3100 1Magnetic Resonance Spectroscopy 1MEDI0457 1Immunoglobulin G 1Disulfides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anal Canal Carcinoma × Magnetic Resonance Spectroscopy × Gynecologic × Clear all
NCT03403465 2026-02-27

Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers

Duke University

Phase 2 Active not recruiting
90 enrolled
GastrointestinalGynecologic

Anal Canal Carcinoma, Uterine Cervical Neoplasms, Esophageal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡